Alto Neuroscience, Inc. (ANRO)
Healthcare
Biotechnology
27.10 $
-5.4%
vs. previous close
Closing price · As of: 31. Jul 2026
Alto Neuroscience, Inc. (ANRO) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -52 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| -9.3 | -20 | -33 | -47 | -52 | |
| 0.1 | 0.3 | 0.4 | 0.5 | 0.7 | |
| 0.2 | 1.8 | 2.9 | 7.6 | 8.1 | |
| -0.6 | 4.6 | -0.7 | 4.1 | 0.0 | |
| 0.7 | 0.7 | 0.5 | 2.1 | 0.0 | |
| -0.7 | -0.7 | -0.5 | -2.1 | 0.0 | |
| – | – | – | 0.0 | -0.2 | |
| 0.0 | 9.8 | 0.0 | 0.0 | 9.5 | |
| 32 | 44 | 68 | 136 | 60 | |
| 22 | 23 | 34 | 86 | 8.3 | |
| -9.9 | -21 | -34 | -49 | -52 |
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.